---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-003852"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:14:44.486468+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Patent settlement with Orbicular allows generic YUPELRI launch on April 23, 2039

## Summary
- Settlement resolves Hatch-Waxman litigation with Orbicular over YUPELRI (revefenacin).
- Orbicular granted royalty-free license to market generic revefenacin on or after April 23, 2039.
- Litigation continues against four other ANDA filers: Cipla, Eugia, Lupin, and Mankind Pharma.
- Settlement subject to review by U.S. DOJ and FTC as required by law.

## SEC filing metadata
- accession: 0001104659-24-003852
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924003852/0001104659-24-003852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924003852/tm243112d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-003852
- JSON: https://secwatch.observer/filing/0001104659-24-003852.json
- Plain text: https://secwatch.observer/filing/0001104659-24-003852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.